The Swedish biotech company has patented the technology that makes "impossible" targets druggable in US and China
Salipro Biotech, a Swedish biotech company with a technology platform for the stabilisation of membrane proteins for drug development, has announced that its patent entitled “Saposin lipoprotein particles and libraries from crude membranes” has been issued by both the US Patent and Trademark Office (U.S. Patent No. 11,346,843B2) and by the China National Intellectual Property Administration (Chinese Patent No. ZL201780050737.6).
The patents cover the company’s novel method of direct extraction of membrane proteins (DirectMX) from cells or crude membranes to enable drug development for challenging drug targets, as well as the generation of Salipro libraries representing the membrane proteome, the particles themselves and their use in drug discovery and membrane protein research, amongst others.
DirectMX is already being implemented in our partnered drug discovery programmes for a range of drug targets, including GPCRs, SLCs and Ion Channels
The Salipro technology enables the development of novel therapeutics against drug targets that previously could not be investigated.
The award of these patents further strengthens Salipro Biotech’s global intellectual property portfolio, with various patents already granted i.a. in the US, EU, China and Japan.
“We are excited to announce the granting of these patents in the US and in China. This news represents an important corporate achievement that fosters our position to accelerate drug discovery programs with pharma companies on challenging drug targets," said Jens Frauenfeld, Salipro CEO.
Maria Knudsen, Business Development Director, added: “DirectMX is already being implemented in our partnered drug discovery programmes for a range of drug targets, including GPCRs, SLCs and Ion Channels. The addition of these patents to our IP portfolio further solidifies Salipro Biotech’s position as a holder of a key drug discovery platform and will enable us to increase the value of our pharma collaborations as well as continue to build our internal pipeline.”